BPC-157 Complete Guide: Research, Safety and Legal Status

What Is BPC 157, and What Does BPC 157 Do?

BPC 157 is a synthetic (lab-made) peptide, a chain of 15 amino acids. Amino acids are the building blocks of proteins. It copies part of a protein found in human gastric juice, the fluid in the stomach. Nearly all the research is in animals. In rodent (rat) studies it guarded and repaired tendon, muscle, gut and nerve tissue.

The full name is Body Protection Compound-157. Researchers at the University of Zagreb in Croatia first made it in the early 1990s. Predrag Sikiric's group described it in 1993, FDA's 2026 review notes. It is a 15-amino-acid fragment of a larger protein first isolated from human gastric juice. In lab tests it resisted breakdown in gastric juice. In rodent (rat) studies, it worked when given by mouth and when injected. A 2021 review by the Zagreb group sums up its wound work in rodents (rats) (Seiwerth et al. 2021).

This is our main guide to BPC 157. It covers how it may work, what the evidence shows, the doses studies used, side effects, the law and sourcing. Where a topic has its own deep dive, we sum it up and point you there.

On dosing, see our BPC-157 dosing article and our page on dosing by body weight.

Affiliate disclosure: this page links to vetted research peptide sellers through our recommended sources page. We earn a fee at no cost to you. Every seller there is checked for third-party testing and openness.

How Does the BPC 157 Peptide Work?

Nobody knows for sure. FDA's 2026 review says its molecular targets have not been identified. It adds that its mechanisms of action remain poorly understood. Lab and rodent (rat) studies point to several paths. Researchers think it may help grow new blood vessels, which is called angiogenesis. In tendon cells it switched on the FAK-paxillin path, a set of signals that helps cells move. It also raised growth hormone receptor levels in those cells.

How does it build new blood vessels?

A 2017 study tested it on human vessel-lining cells in a dish. It raised their levels of VEGFR2, a receptor that drives vessel growth. It also switched on the Akt-eNOS path, which leads to the release of nitric oxide, a gas that relaxes blood vessels. In rodents (rats) with blocked blood flow to a hind leg, blood flow came back faster and more vessels formed (Hsieh et al. 2017).

A 2020 study from the same team used the aorta, the main artery, taken from rodents (rats). BPC 157 widened it, and nitric oxide drove that effect. The authors link it to the Src-Caveolin-1-eNOS path, a chain of signals that turns on nitric oxide production (Hsieh et al. 2020). These are lab and rodent (rat) findings. No study has shown the same in people.

How does it act on tendon cells?

Teams tested it on rodent (rat) tendon fibroblasts in a dish. Fibroblasts are the cells that rebuild tendon. They tested it on ex vivo tendon explants too. Those are small pieces of tendon kept alive outside the body. Cells grew out of the tendon pieces faster. The cells moved better as well. The authors say this is likely driven by two proteins, focal adhesion kinase (FAK) and paxillin. Both help a cell stick down and move (Chang et al. 2011). That paper did not test live animals. It cites earlier work in which cut Achilles tendons healed faster in rodents (rats).

It also lifts growth hormone receptor levels in rodent (rat) tendon fibroblasts. The rise tracks the dose and the time. It shows up in mRNA, the gene's working copy, and in the protein itself. Add growth hormone to the treated cells and they multiply more (Chang et al. 2014).

What does it do in the gut and the brain?

FDA's review describes several rodent (rat) gut studies. In one, rodents (rats) got high doses of NSAIDs, painkillers that can damage the gut. BPC 157 cut the size of the stomach and gut lesions by more than 75%. In another, rodents (rats) had a surgical hole from the colon to the skin, called a fistula. From day 3, treated fistulas were about 40% smaller. It worked by mouth or by injection into the belly. FDA adds that no clear dose-response link, bigger doses giving bigger effects, was found.

A 2020 review looks at how it may protect the gut lining against NSAID damage (Park et al. 2020). Researchers have also tested it in animal models of inflammatory bowel disease (Józwiak et al. 2025).

Brain models point the same way. In one rodent (rat) stroke model, blood flow through the two main neck arteries (the common carotids) was cut for 20 minutes. BPC 157 was applied at the site. At 24 and 72 hours, it counteracted damage to the hippocampus, a memory centre. The rodents (rats) recovered in maze and balance tests (Vukojevic et al. 2020). A 2022 review from the same group sums up this brain work (Vukojevic et al. 2022).

Does BPC 157 Peptide Work in People?

Here is the honest summary. In animals, many studies report benefit. In people the record is close to bare. One review from 2025 found 544 articles. They ran from 1993 to 2024. Of those, 35 preclinical (animal and lab) studies met its bar. Just one clinical study did.

That review found better function, structure and biomechanical (strength and stiffness) scores in animals. The models covered muscle, tendon, ligament and bone injury (Vasireddi et al. 2025).

FDA's 2026 review found one randomised, placebo-controlled trial in patients. People were assigned by chance to the drug or a dummy treatment. It appeared only as a meeting abstract, a short conference summary. It enrolled 53 people with mild to moderate ulcerative colitis, a bowel disease. They took an 80 mg enema, a liquid given into the rectum, or a placebo daily for two weeks. The gap between groups was 1.6 points on a disease score. The likely range around it included zero. FDA called the data inadequate to support that it works or is safe for this use.

FDA lists a few other small human studies. A placebo-controlled safety study gave enemas to 32 healthy volunteers, 24 of them on BPC-157. It too appeared only as meeting abstracts. The rest are a knee pain chart review (a look back at patient records), a bladder study in 12 women, and a two-person drip study. A registered trial of tablets in healthy people has posted no results (NCT02637284).

Why press the point? Animal data shows a thing is worth testing. It does not show a thing works, or that it is safe, in people. The US Anti-Doping Agency (USADA) says no human clinical trials show BPC-157 works for any diagnosis or treatment (USADA).

What Are the Main BPC 157 Benefits in the Research?

The work sits in three main areas.

In rodent (rat) studies, those areas are tendon and ligament repair, muscle healing and gut repair. Rodent (rat) work also covers nerve and spinal cord injury. In one study, a single shot helped rodents (rats) recover tail movement after spinal cord injury (Perovic et al. 2019). None of these uses has been proven in people.

How well does it heal tendon and ligament?

In rodent (rat) studies, BPC-157 promoted healing of cut tendons, FDA's review notes. The tendon cell findings above may help explain that. FDA describes such mechanisms as hypotheses. One rodent (rat) study cut the quadriceps muscle free from the bone. The rodents (rats) got 10 mcg or 10 ng per kg a day by mouth. The treated rodents (rats) showed consistent healing at every check from 1 to 90 days. Untreated rodents (rats) did not heal (Matek et al. 2025).

People stretch that to human tendinopathy (tendon pain and damage), partial tears and recovery after surgery. No trial has tested it. FDA found no clinical studies of BPC-157 in tendonitis.

Why do researchers use it for gut health?

It began as part of a gastric protein, and it resisted breakdown in gastric juice in lab tests. The rodent (rat) gut studies above cover NSAID damage and colon fistulas. Rodent (rat) liver studies also found protection against several toxic challenges, FDA's review notes. No trial has shown a gut benefit in people. Our gut health guide goes deeper.

What about muscle tears and surgery recovery?

FDA's review lists no human study after a muscle tear or surgery. In rodents (rats), the quadriceps study above covers muscle. The effect is not only local. In one rodent (rat) model, blood flow to the hind legs was cut for 45 minutes, then restored. BPC 157 shielded organs far from the legs. The liver, the kidneys and the lungs all showed less tissue damage (Demirtaş et al. 2025).

Is BPC 157 Injection Better Than Oral Capsules?

No study in people has compared the two. FDA found no human data on how the body takes up BPC 157 by mouth, under the skin, in the nose or on the skin. The withdrawn pharmacy nominations proposed capsules, shots under the skin, a nasal spray, a rectal suppository and a skin cream.

In lab tests it resisted breakdown in gastric juice. In rodent (rat) studies, doses by mouth and by injection both worked in gut and liver models. No human study has compared the two.

In animals given it into a vein, it was broken down fast. Its half-life is the time it takes for half a dose to clear. After a single vein dose, it was 15.2 minutes in rodents (rats) and 5.3 minutes in dogs, FDA's review reports. A 2025 review puts it at under 30 minutes (Vasireddi et al. 2025).

FDA also flags a route risk. Shots under the skin and nasal sprays tend to cause more immune reactions than doses by mouth or by the rectum.

Is There a Proven BPC 157 Dosage?

No. There is no FDA-approved product, so there is no approved dose. USADA says it is unknown whether any dose is safe. No full, peer-reviewed trial has shown that any dose works. We would rather say that plainly than dress it up.

FDA lists the doses given in the small human studies. None of them is a guide to use, and none tested a benefit well enough to count.

The rodent (rat) healing studies FDA describes used 10 ng or 10 mcg per kg. In several, both doses worked about equally well. FDA notes that a dose-response link, bigger doses giving bigger effects, was never set. It adds that how much is absorbed by most routes is unknown.

Why Is It Stacked With Thymosin Beta-4?

TB-500 is sold alongside it, sometimes in the same product. Several websites use the names TB-500 and thymosin beta-4 as if they were the same, FDA's TB-500 review notes. They are not.

TB-500 is a seven-amino-acid piece of thymosin beta-4, with a small chemical cap added. That review stresses that TB-500 and thymosin beta-4 are not the same substance. Sellers offer the two peptides in blends, FDA's BPC-157 review found. It lists injections and nasal sprays that hold both.

No controlled trial has given the two together. One chart review of knee pain included people given BPC-157 with thymosin beta-4. FDA's adverse event files hold one report on a BPC-157 and TB-500 blend. The woman's skin and gums darkened, and it happened again when she used it again. The added or synergistic effects users claim, meaning greater together than apart, stay unproven. For the full comparison, read our comparison guide.

What Are the BPC 157 Side Effects and Risks?

FDA's 2026 review says there is not enough clinical safety data to describe its safety profile. The small human studies reported no serious adverse events. In FDA's rules, that means events such as death, a life-threatening problem or a hospital stay. Still, they were short and small, and safety checks were often unclear. In the healthy volunteer enema study, headache and flatulence (wind) were most common. They occurred about as often as on placebo, with no obvious difference. No reported harm is not the same as proven safety.

FDA's adverse event database held three reports up to December 2025, all from injections. One woman had redness and swelling at the shot site for 9 days. She was also injecting compounded (pharmacy custom-made) thymosin, which FDA says limits what the report shows. A man went to an emergency room with shortness of breath. A woman on a BPC-157 and TB-500 blend had her skin and gums darken. FDA could not tell whether BPC-157 caused any of these.

The animal record is mixed. In a one-dose study, rodents (rats) and dogs showed no signs of harm. BPC-157 did not damage genes in lab tests, and it caused no birth defects in a rodent (rat) study. But in 28-day studies, rodents (rats) and dogs showed changes in blood clotting times. FDA also reports liver-associated signals in those studies, such as a raised liver enzyme. FDA says the findings appeared to be associated with clinically relevant safety signals.

Other gaps deserve a name. FDA found no cancer studies. No study has tested effects across a full reproductive cycle. FDA says injected or nasal BPC-157 may pose a significant risk of immune reactions. Clumped peptide and impurities could add to that risk.

A 2025 review describes wide effects in animal models, from tissue injury to bowel and brain disorders (Józwiak et al. 2025). That breadth is where the worry sits. It promotes new vessel growth in rodents (rats), so a theoretical worry is that it could feed a tumour's blood supply. Nobody has studied that in humans. Because so few human studies exist, USADA says it is unknown if there is a safe dose (USADA).

Is BPC 157 Legal to Buy?

BPC-157 is not an FDA-approved drug. FDA found no approved product that holds it in any country. It is sold in the United States as a dietary supplement ingredient, FDA notes. No pharmacy may make it up under section 503A today.

Section 503A of the drug law covers pharmacies that compound (custom-make) a drug. It lets them use a raw bulk ingredient in only three cases. The first is a USP or NF monograph, an official quality standard. The second is being part of an FDA-approved drug. The third is a place on FDA's 503A bulks list, 21 CFR 216.23. FDA's review found BPC-157 has no monograph. It is not part of any approved drug. The bulks list does not name it.

In September 2023, FDA placed BPC-157 in Category 2. That is the group of substances FDA says may present significant safety risks. The Category 2 placement of September 2023 made FDA's position explicit. On 22 April 2026, FDA took it out of Category 2, because the nominations were withdrawn. It did not move to Category 1. FDA still chose to review it for its advisory meeting of 23 and 24 July 2026. A Federal Register notice set BPC-157 for 23 July. In that review, FDA proposed not adding BPC-157 to the bulks list.

FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026. It is a panel of outside experts who advise FDA. The committee recommended BPC-157, KPV, TB-500, MOTS-c, epitalon and Semax for the bulks list, the National Community Pharmacists Association reported. NCPA reported that the committee rejected adding emideltide. The vote is advisory, and FDA's meeting page lists no minutes or vote record. A Federal Register search on 27 September 2026 found no FDA proposed rule to add it. No lawful route exists today to compound it under section 503A. It has never been on the bulks list or in Category 1.

FDA's safety-risk page still lists BPC-157, under substances nominated but withdrawn. A "research use only" label does not make a product lawful to sell for people. In a 2024 warning letter about other research-labelled peptides, FDA said such products were still unapproved new drugs.

Athletes face a separate rulebook. The World Anti-Doping Agency (WADA) first named BPC-157 on its Prohibited List in 2022. It sits under Section S0, which covers non-approved substances. The ban holds in and out of competition. A TUE, or therapeutic use exemption, is a medical waiver. USADA says one is unlikely to be approved for BPC-157, though it weighs each case. In 2025, a U SPORTS volleyball player in Canada got a four-year ban for using BPC-157 and TB-500. The case rested on information submitted to the Canadian Centre for Ethics in Sport (CCES). Our guide to the WADA ban sets out what that means day to day.

How Do You Check Quality Before You Buy?

A certificate of analysis, or CoA, is a lab report on one batch.

FDA looked at CoAs for BPC-157 and found most show only a purity result. They give no limits or results for impurities. FDA also found different salts, slightly different chemical forms, and related molecules sold under the same name. It adds that peptides can clump together, and clumps can raise the risk of immune reactions. Sellers ship it as a freeze-dried powder, and FDA says storage and handling affect its stability.

For sellers who meet third-party testing across many batches, see our recommended sources page. We update it when standards shift. Our supplier vetting checklist walks through the rest.

Where Are the Biggest BPC 157 Safety Gaps?

Human trials barely exist, and the biology touches many systems. For some groups, the gaps in the data are wider than for others.

FDA found no cancer studies, and in rodents (rats) BPC 157 promotes new vessel growth. For anyone with a history of cancer, that leaves a theoretical risk no study has tested. A rodent (rat) study found no birth defects, but no study has covered a full reproductive cycle. The 28-day animal studies found shifts in blood clotting times.

The long-term unknowns are real. Nothing on this page tells you whether it suits you.

References

• FDA 2026 - Evaluation of BPC-157-related bulk drug substances. Briefing document, Pharmacy Compounding Advisory Committee, 23 to 24 July 2026
• Vasireddi N et al. 2025 - Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J
• Chang CH et al. 2014 - Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules
• Chang CH et al. 2011 - The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol
• Hsieh MJ et al. 2020 - Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep
• Hsieh MJ et al. 2017 - Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med
• Józwiak M et al. 2025 - Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals
• Vukojevic J et al. 2020 - The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain Behav
• Vukojevic J et al. 2022 - Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res
• Park JM et al. 2020 - BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Curr Pharm Des
• Perovic D et al. 2019 - Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury. J Orthop Surg Res
• Matek D et al. 2025 - Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle. Pharmaceutics
• Seiwerth S et al. 2021 - Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol
• Demirtaş H et al. 2025 - Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage. Medicina
• ClinicalTrials.gov NCT02637284 - PCO-02 Safety and Pharmacokinetics Trial
• USADA - BPC-157: Experimental Peptide Creates Risk for Athletes
• WADA 2026 Prohibited List
• NCPA 2026 - FDA advisory committee nominates six peptides for pharmacies to compound

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.